About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
SMART QUOTES
Smart
Quotes
Venus Remedies Ltd.
Industry :
Pharmaceuticals & Drugs
BSE Code
526953
ISIN Demat
INE411B01019
Book Value
449.75
NSE Code
VENUSREM
Dividend Yield %
0.00
Market Cap
6295.85
P/E
10.52
EPS
44.75
Face Value
10
BSE
NSE
04-Sep-2025 10:34
BSE
NSE
NSE F & O
04-Sep-2025 10:28
BSE
NSE
NSE F & O
Last Price
478.95
Net Change
16.65
% Change
3.6%
Prev.Close
462.30
Open
472.00
High
478.95
Low
466.65
Volume
269
Last Price
470.05
Net Change
1.9
% Change
0.41%
Prev.Close
468.15
Open
470.00
High
482.65
Low
470.00
Volume
3155
Value
128837.55
Best Buy
470.00
Best Sell
478.95
Best Quantity
27
Sell Quantity
3
Today's Range
478.95
52-Week High
565.95
52-Week Low
272.20
Value
1483007.75
Best Buy
470.05
Best Sell
475.95
Best Quantity
16
Sell Quantity
3
Today's Range
482.65
52-Week High
567.80
52-Week Low
270.25
Open Price
High Price
Low Price
Last Price
Prev Close
Change
% Change
Average Price
Underlying Value
Number of contracts traded
Turnover in Rs. Lakhs
Open Interest
Change in O I
% Change in O I
%
Today
|
1W
|
1M
|
1Y
You need to upgrade your Flash Player
Best Bid
Best Offer
Quantity
27
Price
470.00
Quantity
3
Price
478.95
Best Bid
Best Offer
Quantity
16
Price
470.05
Quantity
3
Price
475.95
Best Bid
Best Offer
Quantity
Price
Quantity
Price
Holding Details
More
Latest Corporate Events
Book Closure
17-Sep-24
23-Sep-24
Dividend
30 %
25-Sep-13
Company News
08-07-2025
Venus Remedies informs a...
22-05-2025
Venus Remedies secures Uk...
22-05-2025
Venus Remedies rises on s...
17-04-2025
USFDA grants QIDP Designa...
25-02-2025
Venus Remedies informs ab...
25-02-2025
Venus Remedies sings lice...
25-02-2025
Venus Remedies jumps on s...
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.